What is the appropriate evaluation and management for a patient with a decreased diffusing capacity for carbon monoxide (DLCO) on pulmonary function testing?

Evaluation and Management of Decreased DLCO

A decreased DLCO requires systematic interpretation alongside spirometry and lung volumes to identify the underlying pathophysiology, with the diagnostic approach determined by the specific pattern of pulmonary function abnormalities. 1, 2

Initial Evaluation Steps

Correct for Technical and Patient Factors

• Always correct DLCO for hemoglobin concentration before interpretation – anemia artificially lowers measured DLCO and can mask the true gas-exchange status, particularly important in patients with autoimmune diseases or chronic illness 2
• Adjust for carboxyhemoglobin levels, especially in active smokers 3
• Verify adequate breath-hold technique – the test requires inhalation to full inflation followed by 10-second breath hold 4, 5

Grade Severity of DLCO Reduction

The European Respiratory Society provides the following severity classification 1:

• Mild: 60% to <LLN (lower limit of normal)
• Moderate: 40-60% predicted
• Severe: <40% predicted

A DLCO <40% predicted is associated with significantly increased morbidity and mortality 3, 5

Diagnostic Algorithm Based on PFT Pattern

Pattern 1: Normal Spirometry + Normal Lung Volumes + Low DLCO

This pattern suggests 1, 2:

• Pulmonary vascular disease (pulmonary hypertension, chronic pulmonary embolism)
• Early interstitial lung disease (before restrictive changes develop)
• Early emphysema (before airflow obstruction manifests)
• Anemia (if not corrected)

Next steps: Obtain high-resolution CT chest to evaluate for early ILD patterns; consider echocardiography or right heart catheterization for pulmonary hypertension; perform 6-minute walk test with continuous pulse oximetry to assess for exertional desaturation 3

Pattern 2: Restrictive Pattern + Low DLCO

This strongly indicates parenchymal lung disease 1, 2, 3:

• Interstitial lung disease (ILD)
• Pulmonary fibrosis
• Sarcoidosis

DLCO reduction is the earliest and most sensitive PFT abnormality in ILD, frequently preceding changes in lung volumes 3

Next steps: High-resolution CT chest is the primary imaging modality; look for usual interstitial pneumonia (UIP) pattern with honeycombing, ground-glass opacities, or reticulation 3

Pattern 3: Restrictive Pattern + Normal DLCO

This suggests extraparenchymal causes 1, 2:

• Chest wall disorders
• Neuromuscular disease
• Shrinking-lung syndrome (in systemic lupus erythematosus)
• Obesity

Pattern 4: Obstructive Pattern + Low DLCO

This pattern strongly suggests emphysema rather than primary airway disease 1, 2, 5

• In adult smokers with post-bronchodilator airway obstruction, a low DLCO greatly increases the probability of the emphysema phenotype of COPD 5
• Even in GOLD stage I COPD (mild obstruction), a DLCO <60% predicted is associated with 3.37-fold increased mortality risk, more dyspnea, lower exercise capacity, and higher BODE index 6

Pattern 5: Obstructive Pattern + High DLCO

This is characteristic of asthma due to increased pulmonary capillary perfusion 1, 2, 7

• A low DLCO in a patient diagnosed with asthma warrants evaluation for alternative or coexisting diagnoses such as emphysema or pulmonary vascular disease 2

Additional Diagnostic Testing

When DLCO is Reduced

• Measure total lung capacity (TLC) by body plethysmography to definitively confirm or exclude restriction – spirometry alone is insufficient 3
• Obtain arterial blood gas to evaluate for hypoxemia or increased alveolar-arterial oxygen gradient 3
• Perform 6-minute walk test with continuous pulse oximetry to assess for exertional desaturation, which may be present even with normal resting PFTs 3
• Search for clinical and laboratory signs suggesting specific ILD etiologies: connective tissue disease markers, hypersensitivity pneumonitis exposures, or drug-induced ILD 3

Monitoring and Prognostic Considerations

Serial Testing

• Serial PFTs every 3-6 months for at least 1 year are required to establish disease trajectory in suspected progressive lung disease 3
• Track DLCO alongside other parameters (VC, TLC) in patients with ILD or severe COPD, as changes in DLCO may be clinically important even when spirometry remains stable 1
• A decline in DLCO of more than 4 units (or 15% relative decline) is associated with increased morbidity and mortality 3, 5

Prognostic Thresholds

• DLCO <45% predicted is associated with poor outcomes and increased mortality in pulmonary fibrosis 3
• DLCO <40% predicted represents severe impairment with significantly increased risk across multiple disease states 1, 5

Common Pitfalls to Avoid

• Failing to correct for anemia leads to falsely low values that do not reflect true gas-exchange impairment 2
• Assuming asthma causes reduced DLCO is physiologically incorrect – asthma characteristically elevates DLCO 2, 7
• Interpreting DLCO in isolation without spirometry and lung volumes prevents accurate differential diagnosis 1, 8
• Using DLCO/VA (KCO) as a "correction" for low alveolar volume is physiologically incorrect – KCO is a rate constant that changes with different pathologies and should be interpreted mechanistically 9
• Tracking too many indices simultaneously increases the risk of false-positive indications of change 1

Disease-Specific Considerations

Systemic Lupus Erythematosus

• High-risk (symptomatic) SLE patients should undergo PFT (spirometry + DLCO) followed by HRCT when indicated 2
• Asymptomatic SLE patients without additional risk factors do not require routine DLCO screening 2
• For high-risk SLE patients, perform annual pulmonary function tests; reserve HRCT for symptoms or abnormal PFT results 2

Post-COVID-19

• Impaired DLCO is the main finding in 52% of critically ill COVID-19 patients at 3-6 months post-discharge, with risk increased by age >60 years, mechanical ventilation requirement, and longer ICU stay 10